Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25564702 | 0.79 | NFE2L2 (0.40) | CYP19A1CETPNFE2L2 | |
| SCHEMBL20466847 | 0.75 | CYP19A1 (0.37) | CYP19A1CETPNFE2L2MAPK1 | |
| SCHEMBL19865805 | 0.73 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL2609326 | 0.70 | CCR9 (0.40) | ALDH1A1CYP19A1NFE2L2CCR9 | |
| SCHEMBL16140172 | 0.69 | SMN1; SMN2 (0.48) | ALDH1A1CYP19A1KDM4EPKMNFE2L2 | |
| SCHEMBL20097920 | 0.68 | TAAR1 (0.47) | KDM4EMAPK1 | |
| SCHEMBL8247564 | 0.67 | FAAH (0.45) | ALDH1A1CYP19A1NFE2L2MAPK1 | |
| SCHEMBL8113207 | 0.67 | SCN10A (0.43) | ALDH1A1CYP19A1NFE2L2 | |
| SCHEMBL25886965 | 0.67 | NFE2L2 (0.41) | CYP19A1CETPNFE2L2 | |
| SCHEMBL18463720 | 0.67 | NFE2L2 (0.37) | ALDH1A1CYP19A1CETPNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | ALDH1A1 2215/4885CYP19A1 2473/4885KDM4E 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.